Ethereum unstaking queue surges by 392%: MetaMask incident may lead to 523,000 ETH waiting to exit
Author: Estefano Gomez
Translation: TechFlow
TechFlow Guide: At the beginning of October, the Ethereum validator exit queue surged by about 392%, peaking at nearly 850,000 ETH waiting in line and an estimated 14.77-day wait; of these, around 523,000 ETH originated from pre-emptive exits by MetaMask Staking following an infrastructure breach, with a strong connection to Lido operations. For ETH and LSD holders, this is a hard signal that short-term selling pressure has been stretched out and single-point infrastructure decisions can influence a much larger staking pool.
A security scare at MetaMask Staking, combined with some apparent profit-taking, pushed the Ethereum validator exit queue to its highest level this year.
According to data circulating on X, since the beginning of October, the amount of unstaked Ethereum has jumped 392%. By October 2, about 850,000 ETH were queued for withdrawal by validators leaving the network.
This is the longest exit queue seen on Ethereum this year. It occurred in the same week that MetaMask Staking notified users some of its infrastructure had been breached.
What’s driving the exit queue up
By October 2, the estimated exit wait time had reached about 14.77 days. In late September, the exit volume was still at a relatively low to mid-range of around 100,000 ETH.
The queue peaked at about 850,000 to 850,736 ETH. Across the network, roughly 43.6 million ETH are staked with about 878,000 active validators. Therefore, the exiting amount was close to 2% of the total staked ETH supply.
The MetaMask Staking incident
On September 30, MetaMask Staking disclosed that part of its infrastructure was breached. About 0.36 ETH, spanning 18 blocks' worth of rewards, was temporarily redirected. MetaMask stated that user wallets and sensitive data were not affected.
MetaMask subsequently initiated the exit of nearly 17,000 validators holding a total of about 523,000 ETH, a significant portion of which was tied to Lido operations. This withdrawal was classified as a precaution and was expected to be completed before October 7.
Of the roughly 850,000 ETH queued to exit, about 523,000 came solely from MetaMask validators.
It’s not all about risk aversion
Litecoin mining pool founder Jiang Zhuoer noted that the surge in the queue suggests some holders are locking in profits at current prices.
Price barely moved
From September 30 to October 2, ETH traded in a narrow range between $2,686 and $2,725. With an exit wait time nearing 14.77 days, any selling pressure will be distributed over time rather than hitting the market all at once.
What does this mean for stakers and the market
MetaMask's withdrawal is expected to be completed before October 7. Once cleared, unless new withdrawals take their place, the queue should shrink noticeably.
Since a significant proportion of the staked ETH being withdrawn is tied to Lido operations, this event highlights how the decisions of a single infrastructure partner can affect a much larger ETH staking pool.
There are still about 43.6 million ETH staked across around 878,000 validators. Even at peak, the exit queue was just a small part of this total.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Alector stock surges after agreement with Genentech on an experimental Parkinson's disease drug
October 5 - The stock price of pharmaceutical company Alector (ALEC.O) surged by 44.20% in pre-market trading, reaching $2.61. The company has entered into a global licensing agreement with Genentech for AL050, an experimental drug developed by ALEC for the treatment of Parkinson's disease. ALEC has granted Genentech the exclusive worldwide rights to develop and commercialize AL050. According to ALEC, the agreement will bring an upfront payment of $100 million and may result in milestone payments of up to $1.17 billion by 2029. The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights to use the platform in its research and development pipeline. As of the close of the previous trading day, ALEC's stock price had risen by 16.03%. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Due to possible errors in automation or lack of context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation.)
How Far Can 12 Straight Wins Take a Trader Who Is Still Down $22.8 Million?
BUZZ - Weakening demand causes Align stock to decline; brokers downgrade rating to "market perform"
October 5 - ** Align Technology (ALGN.O) shares fell 3% in pre-market trading to $139.45 ** Brokerage Evercore ISI downgraded ALGN's rating from "Outperform" to "In Line with the Market" ** The firm cited a "weakening consumer environment," a "sharp slowdown" in September demand indicators, and the potential negative impact of China's volume-based procurement (VBP) in 2027, leading it to adopt a more cautious outlook on Align’s earnings prospects ** VBP (volume-based procurement) is a bulk procurement initiative at the national level in China ** Evercore added that the dental market "has weakened significantly in the third quarter," noting declines in both consumer confidence and expectations ** Deterioration in consumer conditions may have started to affect demand for Invisalign, with Evercore ISI stating that the worsening seen in September "increased the risk that deteriorating consumer conditions may begin to be reflected in Invisalign demand" ** Invisalign is Align’s core business and is projected to contribute approximately $3.2 billions to the company’s total revenue of $4 billions in 2025 ** The broker said early signs of profitability improvement at Align are "beginning to show," but a weak consumer environment and potential VBP headwinds make the process "more challenging" ** As of the previous trading day's close, the stock had declined by about 8% year-to-date.
BUZZ - Insmed shares fall as CFO Sara Bonstein resigns
October 5 - ** Shares of pharmaceutical company Insmed (INSM.O) fell more than 3% in pre-market trading to $107.59. ** Sara Bonstein will resign from her position as Chief Financial Officer, effective October 30. ** Sara will stay on until the end of this month to ensure a smooth transition during the company's release of its Q3 financial results on October 29. ** Before joining Insmed, Sara served as Chief Financial Officer at OncoSec Medical. ** The company reaffirmed its fiscal 2026 performance guidance and has begun the search for the next Chief Financial Officer. ** All 25 brokerages covering the stock remain bullish; the median target price is compiled by LSEG data. ** As of the close of the previous trading day, the stock was down 36.15% year-to-date. (To assist non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides automated translation solely for reader convenience. Reuters accepts no liability for any damage or losses caused by the use of automated translation functionality.)
Crypto prices
More
